Group 1 - The company announced the resignation of Vice President Shen Qi due to work adjustments, effective upon receipt of the resignation letter by the board [2][3] - After resigning, Shen Qi will no longer hold the position of Investment Director but will continue as Chairman of the board for a subsidiary [2] - Shen Qi's departure is not expected to impact the company's normal operations and management, and he did not hold any shares in the company at the time of his resignation [3] Group 2 - The company has entered a restricted exercise period for its stock option incentive plan from October 24 to October 29, 2025, during which all incentive recipients will be restricted from exercising their options [4][5] - The company will apply to the relevant authorities for the necessary procedures regarding the restriction on exercising options [5]

Core Viewpoint - The announcement from Kang En Bei indicates a leadership change within the company, specifically the resignation of Vice President Shen Qi due to work adjustments [1] Group 1 - Shen Qi submitted a written resignation report to the board of directors on October 17, 2025 [1] - Following his resignation, Shen Qi will no longer serve as the company's investment director [1] - Shen Qi will continue to hold the position of chairman at the company's subsidiary, Zhejiang University of Traditional Chinese Medicine Herbal Pieces Co., Ltd. [1]

Core Points - The company announced the resignation of Vice President Shen Qi due to work adjustments [1] - Following the resignation, Shen Qi will no longer serve as the company's investment director but will continue as chairman of the company's subsidiary Zhejiang Chinese Medical University Traditional Chinese Medicine Co., Ltd. [1]

Core Viewpoint - The resignation of Shen Qi, Vice President of Zhejiang Kang En Bei Pharmaceutical Co., Ltd., is due to work adjustments, and he will no longer serve as the investment director but will remain as the chairman of a subsidiary [1] Group 1 - Shen Qi submitted a written resignation report to the board of directors on October 17, 2025 [1] - After resigning from the vice president position, Shen Qi will not hold the role of investment director anymore [1] - Shen Qi will continue to serve as the chairman of Zhejiang University of Traditional Chinese Medicine's Chinese Medicine Decoction Pieces Co., Ltd. [1]

浙江康恩贝制药股份有限公司 关于2022年股票期权激励计划首次授予股票期权 第一个行权期限制行权期间的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国证监会《上市公司股权激励管理办法》《浙江康恩贝制药股份有 限公司2022年股票期权激励计划（草案）》以及中国证券登记结算有限责任公 司上海分公司关于上市公司股票期权自主行权的相关规定，并结合浙江康恩 贝制药股份有限公司（以下简称"公司"）2025年第三季度报告披露计划，现 对处于自主行权期间的公司股票期权进行限制行权，具体情况公告如下： | 股票期权激励计划 | 行权期 | 期权代码 | 可行权期 | | --- | --- | --- | --- | | 2022年股票期权激励 | 首次授予股票 | 1000000270 | 2024年11月28 | | 计划 | 期权第一个行 | | 日至2025年11 | | | 权期 | | 月27日 | 证券代码：600572 证券简称：康恩贝 公告编号：临2025-051 2025年10月18日 特此公告。 浙江康 ...

重要内容提示： 浙江康恩贝制药股份有限公司（以下简称"公司"）董事会于 2025 年 10 月 17 日收到 公司副总裁沈旗先生递交的书面辞职报告，因工作调整原因，沈旗先生向公司董事会申请 辞去副总裁职务。沈旗先生辞去副总裁职务后，将不再担任公司投资总监职务，仍担任公 司控股子公司浙江中医药大学中药饮片有限公司董事长职务。 证券代码：600572 证券简称：康恩贝 公告编号：2025-050 浙江康恩贝制药股份有限公司 关于高级管理人员离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （二）离任对公司的影响 根据《中华人民共和国公司法》《公司章程》等有关规定，沈旗先生的辞职 自公司董事会收到辞职报告时生效。沈旗先生的离任不会影响公司的正常运作及 经营管理。截至本公告披露日，沈旗先生未持有公司股份。 沈旗先生在任职期间恪尽职守，勤勉尽责，公司及董事会对沈旗先生在任职 期间所作的贡献表示衷心感谢！ 特此公告。 浙江康恩贝制药股份有限公司董事会 2025 年 10 月 18 日 一、董事/高级管理人员离任情况 （一）提前离 ...

Core Viewpoint - The company announced the resignation of Vice President Shen Qi due to work adjustment reasons, effective immediately upon receipt of the resignation letter by the board [1] Group 1 - Shen Qi will no longer serve as Vice President and will also step down from the position of Investment Director [1] - Despite resigning from these roles, Shen Qi will continue to hold the position of Chairman at the company's subsidiary, Zhejiang University of Traditional Chinese Medicine Herbal Pieces Co., Ltd. [1]

Core Viewpoint - 康恩贝 is actively seeking acquisition opportunities in line with its strategic focus on traditional Chinese medicine and health, considering various factors for potential targets [1] Group 1: Acquisition Strategy - The company evaluates acquisition targets based on strategic alignment, revenue and profit size, growth potential, and compatibility with existing treatment areas and marketing channels [1] - The acquisition efforts are progressing as planned and will be disclosed in future updates [1]

Group 1 - The company does not currently offer special discount activities for shareholders [2] - The company's health consumer products, such as protein powder, vitamins, and probiotics, can be purchased through official flagship stores on platforms like Tmall, JD.com, Pinduoduo, and Douyin [2]

Core Viewpoint - The announcement details the stock option incentive plan of Zhejiang Kangnbei Pharmaceutical Co., Ltd. for the third quarter of 2025, highlighting the number of shares exercised and the related procedures [1][2]. Summary by Sections Stock Option Exercise Details - In the third quarter of 2025, a total of 3.604973 million shares were exercised under the 2022 stock option incentive plan [2]. - The exercised shares will be tradable on the second trading day after the exercise date [2]. Decision-Making Process and Information Disclosure - The plan was approved by the board and supervisory committee in September 2022, with detailed disclosures made on the Shanghai Stock Exchange and other designated media [2][3]. - The plan included the granting of 70 million stock options to eligible participants, with the first grant completed in November 2022 [3]. Adjustments to Stock Option Terms - The exercise price of the stock options was adjusted from 4.13 CNY to 3.98 CNY in June 2023, and further adjustments were made in July 2024 and June 2025 [3][4][5]. - The number of stock options granted was also adjusted, with 752.5 thousand reserved options granted in October 2023 [3][4]. Shareholder and Management Participation - A total of 97 participants exercised their options in the third quarter of 2025 [7]. - The shares resulting from the exercise are subject to a six-month lock-up period for directors and senior management [10]. Financial Impact and Fund Utilization - The exercise of options raised approximately 13.086052 million CNY, contributing to a total of 69.266768 million CNY raised to date, which will be used to supplement the company's working capital [12]. - The impact of the exercised shares on the company's financial status and operational results is not considered significant [12].